Abstract
In The Lancet Haematology, Mehdi Hamadani and colleagues1 report a large phase 1 study of the feasibility, safety, and activity of camidanlumab tesirine, an antibody–drug conjugate comprising a human anti-CD25 monoclonal antibody conjugated to a pyrrolobenzodiazepine dimer via a cleavable linker. After binding to CD25 present on lymphoma cells and normal activated B cells and T cells, camidanlumab tesirine enters the tumour cell by endocytosis, the linker is cleaved, and pyrrolobenzodiazepine causes death of the tumour cell via DNA cross-linking.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
